Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
LIPOSYN II 10% is an intravenous lipid emulsion containing safflower oil and soybean oil used as a source of essential fatty acids and calories in parenteral nutrition. It provides nutritional support for patients unable to take oral or enteral nutrition. The product works by supplying lipids, fat-soluble vitamins, and energy substrate directly into the bloodstream.
As an aging injectable nutritional product with LOE approaching, the brand team is likely focused on defending market share against generic lipid emulsion competitors rather than driving growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on LIPOSYN II offers limited career growth opportunities given the product's mature, commoditized status and approaching LOE. Roles are concentrated in defensive commercial functions—pricing, contracting, and supply chain management—rather than strategic brand-building or clinical innovation.
Worked on LIPOSYN II 10% at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.